SRI V.V. KRISHNA REDDY
I thank all the members for giving me an opportunity to serve you as the National President of Bulk Drug Manufacturers Association (India).
Our 26th Annual General Body Meeting was held on 22nd September 2017. It was a pleasant surprise to have second generation entrepreneurs joining the meeting.
First and foremost I wish to thank the members for their active support which has helped BDMA to complete 26 eventful years.
The Bulk Drug Manufacturers Association (India) was established in the year 1991 with Hyderabad as its Head Quarters. This is an all India body representing the Bulk Drug Manufacturers of India and I have the privilege of serving the association in various capacities.BDMA aims at consolidation of gains of the industry and serves as a coordinator and catalyst between the government and the industry for the growth and sustainability of the industry.
The Indian Pharmaceutical Industry has witnessed a robust growth over the past few years. India now ranks 3rd world wide by volume of production and 14th by value, thereby accounting for around 10% of world’s production by volume and 1.5% by value. Globally, it ranks 4th in terms of generic production and 17th in terms of export value of bulk actives and dosage forms. Indian exports are destined to more than 200 countries around the globe including highly regulated markets of US, West Europe, Japan and Australia. It has shown tremendous progress in terms of infrastructure development, technology base creation and a wide range of products. The industry now produces bulk drugs belonging to all major therapeutic groups requiring complicated manufacturing technologies. Strong scientific base and highly skilled technical manpower and pioneering work done in process development have made this a reality.
India is the country with largest number of US-FDA compliant plants (more than 262 including APIs) outside of USA. We have nearly 1400 WHO-GMP approved Pharma Plants, 253 European Directorate of Quality Medicines (EDQM) approved plants with modern state of the art Technology. No other country can boast of such an infrastructure.
I am glad to say that Indian Bulk Drug and Pharmaceutical Companies are using latest technologies to keep the environment safe and hygienic. Almost all the Indian Bulk Drug and Active Pharmaceutical Ingredient companies had installed online flow meters and cameras of the effluents discharge lines and the same are monitored on real time basis by Central Pollution Control Board and State Pollution Control Boards. In this regard BDMA had continuously pursued to see that our members comply with directions and also advised to maintain environmental compliance. As compared to earlier days the industries are now more environment friendly and all most all our member industries either have Zero liquid Discharge facilities or the generated effluents are sent to CETPs for treatment and final disposal.
The Executive Committee with the support of the members, has represented various issuesbeing faced by the industry to authorities concerned (at State and Central Government level).I request all the members to bring the common issues being faced by the Industry to the notice of BDMA, so that, they can be represented through a common platform for a viable solution.
I WISH YOU ALL THE BEST